S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD
OncLive® On Air - Ein Podcast von OncLive® On Air
Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.
